For this reason, to reliably compare cholangiocarcinoma and PDAC, two subgroups may be needed to further depict an independent role of syndecan-1, namely, KRAS-mutated and KRAS-wildtype tumors. Here, KRAS is linked to cholangiocarcinoma.